Your browser doesn't support javascript.
loading
The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women.
Yang, Wenhui; Hong, Tianpei; Chang, Xu; Han, Meng; Gao, Hongwei; Pan, Bailin; Zhao, Zhenmin; Liu, Ye.
Afiliación
  • Yang W; Department of Plastic Surgery, Peking University Third Hospital, Beijing, China.
  • Hong T; Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.
  • Chang X; Department of Plastic Surgery, Peking University Third Hospital, Beijing, China.
  • Han M; Department of Medical Psychology, The School of Health Humanities, Peking University, Beijing, China.
  • Gao H; Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.
  • Pan B; Department of Plastic Surgery, Peking University Third Hospital, Beijing, China.
  • Zhao Z; Department of Plastic Surgery, Peking University Third Hospital, Beijing, China.
  • Liu Y; Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.
Int J Transgend Health ; 25(3): 471-482, 2024.
Article en En | MEDLINE | ID: mdl-39055628
ABSTRACT

Objective:

Cyproterone acetate (CPA) and spironolactone (SPL) are different antiandrogens in gender-affirming hormone therapy (GAHT) for transgender women. Few studies have evaluated their efficacy and user satisfaction, especially among East Asians. This study aimed to evaluate these aspects in Chinese transgender women.

Methods:

Data were collected retrospectively from transgender women visiting the Peking University Third Hospital from 2012 to 2021. From 639 people identified as transgender women, 151 of them (80 using CPA and 71 using SPL, 16 to 40-year-old) under stable GAHT ≥6 months were enrolled. Total testosterone levels and visual analogue scale (VAS)-based satisfaction scores were evaluated.

Results:

No difference was observed in age between the CPA and SPL groups (median [IQR], 22 [20-24] years and 23 [20-26] years, respectively). The duration of GAHT was longer in CPA group than in SPL group (18 [10-32] months vs. 12 [8-21] months, p = 0.009). Total testosterone levels were significantly lower with CPA treatment (25 mg/d) than with SPL treatment (100 mg/d) (median [IQR] 0.7 [0.7-2.1] nmol/L vs. 13.0 [6.0-17.8] nmol/L, p < 0.001). The proportion of total testosterone levels reaching the recommended range was significantly higher in CPA group than in SPL group (75.0% vs. 11.3%, p < 0.001). VAS-based satisfaction scores for erection decreased and figure feminization were higher in CPA group than in SPL group, which remained unchanged after adjusting for age, treatment duration, estradiol dose, and comorbid mental disorders (p < 0.05). The prolactin levels were higher in CPA group than in SPL group (18.9 [11.8-28.1] ng/ml vs. 11.8 [7.9-18.4] ng/ml, p < 0.001). No severe safety events were reported in both groups.

Conclusion:

In Chinese transgender women, CPA was more effective than SPL in lowering testosterone levels. Additionally, VAS scores indicated greater satisfaction with erection decreased and figure feminization using CPA compared to SPL.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Transgend Health Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Transgend Health Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos